全球mRNA治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

mRNA疗法市场预计将从2025年的215.2亿美元成长到2034年的906亿美元，2026年至2034年的复合年增长率为17.32%。

由于传讯RNA技术的进步及其在治疗多种疾病的潜力，全球mRNA疗法市场正经历快速成长。 mRNA疗法透过将遗传讯息传递给细胞，使其产生能够预防或治疗疾病的特定蛋白质。近年来，这种创新方法引起了广泛关注，尤其是在疫苗研发领域的成功。

生技公司和研究机构正在探索基于mRNA的治疗方法，用于治疗方法癌症、遗传性疾病、感染疾病等。 mRNA技术的柔软性使科学家能够快速设计治疗方法并针对特定的疾病机制。递送系统（例如脂质奈米颗粒）的进步也提高了基于mRNA的疗法的稳定性和疗效。

随着临床研究不断证实mRNA疗法的潜力，市场预计将持续成长。製药公司正大力投资开发利用该技术的新治疗方法。在生物技术快速发展的背景下，mRNA疗法有望在下一代医学中发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球mRNA治疗市场：依应用领域划分

• 市场分析、洞察与预测
• 感染疾病
• 肿瘤学
• 罕见遗传疾病
• 呼吸系统疾病
• 其他的

第五章 全球mRNA治疗市场：依类型划分

• 市场分析、洞察与预测
• 预防
• 治疗

第六章：全球mRNA治疗市场：依最终用途划分

• 市场分析、洞察与预测
• 医院和诊所
• 研究机构
• 其他的

第七章 全球mRNA治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Moderna Inc
  • BioNTech SE
  • CureVac NV
  • Arcturus Therapeutics Holdings Inc
  • Sanofi
  • GlaxoSmithKline Plc
  • Argos Therapeutics Inc
  • Ethris GmbH
  • Pfizer Inc
  • AstraZeneca Plc

The mRNA Therapeutics Market size is expected to reach USD 90.60 Billion in 2034 from USD 21.52 Billion (2025) growing at a CAGR of 17.32% during 2026-2034.

The global mRNA therapeutics market is experiencing rapid growth due to advancements in messenger RNA technology and its potential to treat a wide range of diseases. mRNA therapeutics work by delivering genetic instructions to cells, enabling them to produce specific proteins that can prevent or treat diseases. This innovative approach has gained significant attention in recent years due to its success in vaccine development.

Biotechnology companies and research institutions are exploring mRNA-based treatments for conditions such as cancer, genetic disorders, and infectious diseases. The flexibility of mRNA technology allows scientists to design therapies quickly and target specific disease mechanisms. Advances in delivery systems, such as lipid nanoparticles, are also improving the stability and effectiveness of mRNA therapeutics.

In the future, the market is expected to grow as clinical research continues to demonstrate the potential of mRNA-based treatments. Pharmaceutical companies are investing heavily in developing new therapeutic applications using this technology. As biotechnology innovation progresses, mRNA therapeutics are likely to become an important part of next-generation medical treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

By Type

• Prophylactic
• Therapeutic

By End-use

• Hospitals & Clinics
• Research Organizations
• Others

COMPANIES PROFILED

• Moderna Inc, BioNTech SE, CureVac NV, Arcturus Therapeutics Holdings Inc, Sanofi, GlaxoSmithKline plc, Argos Therapeutics Inc, Ethris GmbH, Pfizer Inc, AstraZeneca plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Respiratory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MRNA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MRNA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MRNA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Type
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Type
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Type
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Type
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Type
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MRNA THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Moderna Inc
  • 9.2.2 BioNTech SE
  • 9.2.3 CureVac N.V
  • 9.2.4 Arcturus Therapeutics Holdings Inc
  • 9.2.5 Sanofi
  • 9.2.6 GlaxoSmithKline Plc
  • 9.2.7 Argos Therapeutics Inc
  • 9.2.8 Ethris GmbH
  • 9.2.9 Pfizer Inc
  • 9.2.10 AstraZeneca Plc